• Molecular NameFlunarizine
  • Synonym(E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; Flunarizina [inn-spanish]; flunarizine dihydrochloride; Flunarizine Hydrochloride; Flunarizinum [inn-latin]
  • Weight404.504
  • Drugbank_IDDB04841
  • ACS_NO52468-60-7
  • Show 3D model
  • LogP (experiment)5.78
  • LogP (predicted, AB/LogP v2.0)5.48
  • pkaN/A
  • LogD (pH=7, predicted)4.42
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.51
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds6
  • TPSA6.48
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug classified as a calcium channel blocker. Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.
  • Absorption_value80.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A